Information Library
Phase IIIB/IV
To learn more about a particular aspect of Quintiles’ pharma services, biotech development or drug commercialization services, select a topic at left. If you’ve already specified a choice, you may narrow your search by selecting additional categories in any order. For example, for information on oncology drug development, start by selecting oncology. Then you can narrow your search to Central Lab, News Releases and Europe.
- Sort by: Most Recent
- Title
-
Coordinating Safety Across Functions and Phases
November 3, 2009
A customer faced significant challenges with clinical and post-marketing safety. Without previous drug safety experience, they needed an ally who could provide a full range of safety and risk management solutions. -
Enhancing a Culture of Safety in the Life Sciences Sector
October 6, 2009
Axel Olsen, Executive Director of Global Pharmacovigilance and Risk Management, stresses that stakeholder collaboration is the key to improving drug safety. -
What if You Could Expect More from Late Phase
October 1, 2009
Quintiles and Cerner share how you can get more from your late phase efforts. -
QUINTILES AND CERNER WORK TOGETHER TO IMPROVE EFFICIENCY OF LATE PHASE RESEARCH STUDIES
October 1, 2009 – Quintiles, the only fully integrated biopharmaceutical services company offering clinical, commercial, consulting -
Emerging Markets
September 29, 2009
If you’re looking for new ways to bring development costs down, you may be considering the advantages of conducting clinical trials in emerging markets. -
QUINTILES INCREASES CAPACITY TO SUPPORT EUROPEAN CLINICAL TRIALS
September 24, 2009 - Quintiles Transnational Corp. today announced the opening of an expanded regional facility near Edinburgh, Scotland. Located within the Alba Campus, a research and development center near Edinburgh, the 115,000-square-foot building hosts more than 500 employees and has space for Quintiles Clinical Development Services, including Project Management, Regulatory Affairs and Data Management. -
Maximizing Post-Marketing Research for Robust ROI
September 18, 2009
Quintiles leveraged its expertise and resources in a large-scale observational study to produce valuable post-marketing data for commercial success. -
Diabetes Outcomes
September 8, 2009
This Phase IIIB diabetes study involved cardiovascular outcomes assessed over 6 years. Learn how Quintiles helped the customer overcome the challenges of patient retention, data collection and evaluation. -
Changing the Face of Cancer Research
August 31, 2009
Christopher Ung, Vice President, Strategic Business & Operations, Oncology, at TMD, a Quintiles Central Laboratory, explains how advances in biomarker technology are ushering in a new era of cancer therapy development. -
Post-Marketing Commitment Study
June 30, 2009
Quintiles developed creative and effective solutions to deliver quality data, cost efficiently and ahead of schedule.